What Does Your Ki-67 Score Mean for Cancer Prognosis?

Your Ki-67 score measures how fast your cancer’s cells are multiplying. A higher score usually signals a faster-growing tumor and a somewhat higher risk of the cancer coming back.¹ But fast-dividing cancers are also the ones chemotherapy hits hardest, so a high score can mean a better chance that treatment works.² The number helps shape which treatment fits you rather than deciding how things will turn out.

What the Ki-67 Number Actually Counts

Ki-67 is a protein that appears in a cell’s nucleus whenever the cell is preparing to divide or is dividing.³ It disappears from cells that are resting.⁴ Normal tissues such as skin and the lining of the gut also divide constantly, so some Ki-67 is not unusual on its own. Counting the cells that carry it shows what share of the tumor was growing at the moment the sample was taken.

To get your percentage, a thin slice of your biopsy is stained so that cells with Ki-67 turn a visible color.⁵ A pathologist then counts roughly 500 to 2,000 tumor cells, marking each as stained or not.⁶ The Ki-67 index on your report is the stained tumor cells divided by all the tumor cells counted, times 100.⁷

On your pathology report, the result usually appears as a percentage. Some reports label it “proliferation index” or “MIB-1.” MIB-1 is the name of the stain used, not a separate test. A score of 30% means about 3 in 10 of the counted cancer cells were dividing or preparing to divide. The number sits alongside the tumor’s grade, its hormone receptors and its HER2 status, and all of these are read together.

The biopsy sample is small. A needle biopsy takes only a sliver of the tumor, and cells within one tumor do not all divide at the same rate. Tumors often have busier and quieter regions, which is one reason the same cancer can give a somewhat different score from a biopsy than from the surgical specimen.

Low, Intermediate or High Ki-67 in Breast Cancer

Several cutoffs are in use, so the one on your report may differ from what you read elsewhere:

The 14% figure came from early research that used Ki-67 to separate luminal A from luminal B tumors. The 20% figure was adopted later by many labs and groups looking at how patients actually did, which is why it is more common on current reports. Because labs have not settled on one rule, the same score can be called low by one report and borderline by another. If your score falls between 14% and 20%, ask which cutoff your care team follows, because that decides whether the label on your report sounds reassuring.

In hormone receptor-positive, HER2-negative breast cancer (cancer that is fed by hormones and does not carry extra HER2 protein), scores under 14% and scores of 14 to 19% carried the same, better outlook.¹² Scores of 20% or higher were linked to a higher risk of recurrence and death.¹³ The link between higher Ki-67 and worse outlook holds across a wide range of cutoffs, so no single number is a sharp line.¹⁴

The middle range is the hardest to read. Labs agree best on very low or very high scores, and agreement is weakest for scores in between.¹⁵

A high score means the tumor is growing faster, not that it cannot be treated, and fast-growing breast cancers are often treated with success. Your overall outlook comes from several features taken together, including stage, tumor size, lymph node involvement and grade, with Ki-67 as one of them. Outlook figures describe what happened to large groups of people, so they cannot predict what will happen in your case.

Why a High Score Can Mean Better Response to Chemotherapy

Chemotherapy works mainly by attacking cells that are dividing. So in breast cancer treated with chemo before surgery, high-Ki-67 tumors were about four times as likely to leave no cancer at surgery.¹⁶ Doctors call that outcome a pathologic complete response, or pCR, a term you may hear.¹⁷ In one group, a cutoff near 25% best predicted response, especially in hormone-negative and HER2-positive cancers.¹⁸ The outlook is worst when a fast-growing tumor does not respond to chemotherapy.¹⁹²⁰

If your score is high, your team may recommend chemotherapy before or after surgery, because fast-growing tumors tend to respond to it. Treatment before surgery has an added benefit: it shows how your tumor responds, and that response can guide what comes next. Only the surgical specimen can confirm a complete response, so you will not know the result until after your operation, even if scans looked encouraging earlier.

If your score is low, the picture reverses. Slower tumors gain less from chemo, and hormone therapy often does more of the work. A low score, together with other tests, can help some people avoid chemotherapy.

How Ki-67 Shapes Treatment Decisions

In hormone-sensitive breast cancer, a score of 20% or higher can mark people who may benefit from chemo before hormone therapy.²¹ But Ki-67 matches genomic tests such as Oncotype DX only partly.²² Most studies do find that higher Ki-67 goes with higher Oncotype scores.²³ So doctors often order a genomic test when Ki-67 alone leaves the choice unclear. Genomic tests look at the activity of a panel of genes in the tumor and produce a recurrence score, a different kind of measurement from counting dividing cells.

Ki-67 can also be watched over time. Hormone therapy slows cancer cell division, so it lowers Ki-67 if it is working.²⁴ In some cases hormone therapy is given for a few weeks before surgery, and the tissue removed at surgery is tested again. A repeat score after those weeks can show whether the tumor is sensitive to the treatment in your own body.²⁵

That early change may predict long-term results better than tumor size does.²⁶ A strong drop can identify people who may safely receive less treatment, so your team may feel more confident about avoiding chemotherapy.²⁷ If the score stays high, the tumor is probably not responding well to hormone therapy alone, and your team may consider adding other treatment.

How Reliable Is Your Ki-67 Score

Use of Ki-67 has been limited by different readers and labs getting different scores.²⁸ Much of the difference comes from how labs stain the tissue.²⁹ Staining is a chemical process, and small differences in how a lab prepares the slide can make more or fewer cells appear marked. Pathologists also make judgment calls, such as whether faintly stained cells are positive.

Counting methods differ too, such as averaging several areas versus scoring the busiest area.³⁰ Averaging across the whole tumor usually gives a lower number than scoring only the busiest spot. A difference of a few points between two reports does not necessarily mean the tumor changed. Training to a standard method improves agreement between readers.³¹

Computers are helping. With an AI counting tool, pathologists’ average error fell from about 6 points to about 2.³² In another test, disagreement between pathologists fell by about 82%.³³ These tools apply the same rule to every cell and do not tire, but they support the pathologist, and the final report still comes from a physician reviewing the slide. If your score is within a few points of 20% and the treatment choice hinges on it, asking for a second look is reasonable.

Ki-67 in Other Cancers

In neuroendocrine tumors of the gut and pancreas, Ki-67 helps set the tumor’s grade.³⁴ Grades run from low (G1) to high (G3).³⁵ The grade shapes how closely the tumor is monitored and treated. Differences of just 1% to 5% can change the grade,³⁶ so precise counting matters more here than in breast cancer.

In meningioma, higher Ki-67 is linked to shorter survival and more regrowth,³⁷ which can influence how often follow-up scans are scheduled. Even in grade I meningiomas, which are usually considered slow, a score of 3% or more carried a much higher chance of returning,³⁸ so such tumors may be followed as closely as grade II ones.³⁹ In glioma, a positive Ki-67 roughly doubled the risk of recurrence after surgery,⁴⁰ though it is read together with the tumor’s type and genetic features.

In mantle cell lymphoma, Ki-67 is one of the strongest single predictors of outlook,⁴¹ and it is used when planning treatment intensity. In prostate cancer needle biopsies, scores above 5% were tied to a higher risk of dying of the cancer.⁴² The prostate score adds most information in lower-grade cancers,⁴³ where it can show that a seemingly mild cancer deserves more attention. It is used alongside Gleason grade, PSA level and imaging, not on its own.

A breast cancer number cannot be carried over to other tumors. A 5% score is high in prostate cancer but low in breast cancer, and each cancer type has its own scale. Ask your doctor what is considered high for your tumor type.